Aerovate Therapeutics Inc

NASDAQ:AVTE   1:00:00 PM EDT
18.67
+0.41 (+2.24%)
1:08:36 PM EDT: $18.67 0.00 (0.00%)
Earnings Announcements

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

Published: 11/14/2022 12:58 GMT
Aerovate Therapeutics Inc (AVTE) - Aerovate Therapeutics Announces Third Quarter 2022 Financial Results.
Aerovate Therapeutics - Expect Cash, Cash Equivalents and Short-term Investments Will Be Sufficient to Fund Operations Into Second Half of 2025.
Qtrly Loss per Share $0.56.
Cash, Cash Equivalents and Short-term Investments Totaled $142.6 Million As of September 30, 2022.
Q3 Earnings per Share View $-0.50 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.55

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.55

More details on our Analysts Page.